An open-label multicenter phase II study of oral lapatinib (GW572016) as single agent, second-line therapy in patients with metastatic colorectal cancer

Anthony Fields(CHU Dijon Bourgogne), M. S. Berger(Duke University), Luis Chu(Sarah Cannon), Colin Germond(Northeast Cancer Centre), David Rinaldi(GlaxoSmithKline (Canada)), L. Leopold(GlaxoSmithKline (Canada)), Kimberli J. Brill(GlaxoSmithKline (Canada)), Charles Henderson(GlaxoSmithKline (Canada))

Journal of Clinical Oncology

June 1, 2005

10.1200/jco.2005.23.16_suppl.3583

Cited by 48

Related Papers

Adjuvant Chemotherapy After Potentially Curative Resection of Metastases From Colorectal Cancer: A Pooled Analysis of Two Randomized Trials

|Journal of Clinical Oncology|2008|582

Selective Ablation of Acute Myeloid Leukemia Using Antibody-Targeted Chemotherapy: A Phase I Study of an Anti-CD33 Calicheamicin Immunoconjugate

|Blood|1999|456

Selective Ablation of Acute Myeloid Leukemia Using Antibody-Targeted Chemotherapy: A Phase I Study of an Anti-CD33 Calicheamicin Immunoconjugate

|Blood|1999|439

Characterization of A1, a novel hemopoietic-specific early-response gene with sequence similarity to <i>bcl-2</i> .

|The Journal of Immunology|1993|336

Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin)

|Leukemia|2002|224